Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711

J Urol. 2016 Apr;195(4 Pt 1):1172-3. doi: 10.1016/j.juro.2015.11.040. Epub 2016 Jan 16.

Authors

Stacy Loeb¹, Mats Lambe², Pär Stattin³

Affiliations

¹ Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, New York. Electronic address: stacyloeb@gmail.com.
² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
³ Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå; Department of Urology, Uppsala University Hospital, Uppsala, Sweden.

PMID: 26783933
DOI: 10.1016/j.juro.2015.11.040

No abstract available

Publication types

Letter
Comment

MeSH terms

Erectile Dysfunction*
Humans
Male
Melanoma
Phosphodiesterase 5 Inhibitors*
Risk
Skin Neoplasms

Substances

Phosphodiesterase 5 Inhibitors